Antiemetic prophylaxis with temozolomide: an audit from a tertiary care center.

Vijay M PatilArun ChandrasekharanDilip Harindran VallatholMridul MalhotraRam AbhinavPriti AgarwalAnu RajpurohitRaees TonseAtanu BhattacharjeeRakesh Jalali

Published in: Neuro-oncology practice (2019)

The combination of ondansetron with olanzapine leads to a statistically significant decrease in the rate of moderate-to-severe emesis and nausea and needs to be explored in a prospective study.

Keyphrases

chemotherapy induced
tertiary care
high intensity
early onset
newly diagnosed
drug induced